Targeting LRRK2 mutations in Parkinson's disease

被引：1
|
作者：
Lesniak, Robert K. [1 ,2 ]
Nichols, Robert Jeremy [2 ]
Smith, Mark [1 ]
Montine, Thomas J. [2 ]
机构：
[1] Stanford Univ, Sarafan ChEM H, Med Chem Knowledge Ctr, Stanford, CA 94305 USA
[2] Stanford Univ, Dept Pathol, 300 Pasteur Dr, Stanford, CA 94305 USA
来源：
FUTURE MEDICINAL CHEMISTRY | 2022年 / 14卷 / 16期
关键词：
computational chemistry and molecular modeling; drug design; drug discovery; inflammation therapeutics; neurological therapeutics; pharmacokinetics; pharmacodynamics; rare diseases; IDENTIFICATION; METAANALYSIS; DISCOVERY; DESIGN;
D O I：
10.4155/fmc-2022-0102
中图分类号：
R914 [药物化学];
学科分类号：
100701 ;
摘要：
[No abstract available]
引用
收藏
页码：1167 / 1170
页数：4
相关论文
共 50 条
  • [1] LRRK2 Targeting Strategies as Potential Treatment of Parkinson's Disease
    Wojewska, Dominika Natalia
    Kortholt, Arjan
    BIOMOLECULES, 2021, 11 (08)
  • [2] Targeting leucine-rich repeat kinase 2 (LRRK2) for the treatment of Parkinson's disease
    Domingos, Sofia
    Duarte, Teresa
    Saraiva, Lucilia
    Guedes, Rita C.
    Moreira, Rui
    FUTURE MEDICINAL CHEMISTRY, 2019, 11 (15) : 1953 - 1977
  • [3] LRRK2 mutations in patients with Parkinson's disease from Peru and Uruguay
    Mata, Ignacio F.
    Cosentino, Carlos
    Marca, Victoria
    Torres, Luis
    Mazzetti, Pilar
    Ortega, Olimpio
    Raggio, Victor
    Aljanati, Ruth
    Buzo, Ricardo
    Yearout, Dora
    Dieguez, Elena
    Zabetian, Cyrus P.
    PARKINSONISM & RELATED DISORDERS, 2009, 15 (05) : 370 - 373
  • [4] Development of LRRK2 Kinase Inhibitors for Parkinson's Disease
    Galatsis, Paul
    Henderson, Jaclyn
    Kormos, Bethany L.
    Hirst, Warren D.
    ANNUAL REPORTS IN MEDICINAL CHEMISTRY, VOL 49, 2014, 49 : 43 - 58
  • [5] Genetic analysis of LRRK2 mutations in patients with Parkinson disease
    Deng, Hao
    Le, WeiDong
    Guo, Yi
    Hunter, Christine B.
    Xie, WenJie
    Huang, Maosheng
    Jankovic, Joseph
    JOURNAL OF THE NEUROLOGICAL SCIENCES, 2006, 251 (1-2) : 102 - 106
  • [6] LRRK2 in Parkinson's disease: biochemical functions
    Anand, Vasanti S.
    Braithwaite, Steven P.
    FEBS JOURNAL, 2009, 276 (22) : 6428 - 6435
  • [7] Coding and Noncoding Variation in LRRK2 and Parkinson's Disease Risk
    Lake, Julie
    Reed, Xylena
    Langston, Rebekah G.
    Nalls, Mike A.
    Gan-Or, Ziv
    Cookson, Mark R.
    Singleton, Andrew B.
    Blauwendraat, Cornelis
    Leonard, Hampton L.
    MOVEMENT DISORDERS, 2022, 37 (01) : 95 - 105
  • [8] Nanobodies as allosteric modulators of Parkinson's disease-associated LRRK2
    Singh, Ranjan K.
    Soliman, Ahmed
    Guaitoli, Giambattista
    Stoermer, Eliza
    von Zweydorf, Felix
    Dal Maso, Thomas
    Oun, Asmaa
    Van Rillaer, Laura
    Schmidt, Sven H.
    Chatterjee, Deep
    David, Joshua A.
    Pardon, Els
    Schwartz, Thomas U.
    Knapp, Stefan
    Kennedy, Eileen J.
    Steyaert, Jan
    Herberg, Friedrich W.
    Kortholt, Arjan
    Gloeckner, Christian Johannes
    Versees, Wim
    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2022, 119 (09)
  • [9] Olfaction in LRRK2 Linked Parkinson's Disease: Is It Different from Idiopathic Parkinson's Disease?
    Vilas, Dolores
    Tolosa, Eduard
    Quintana, Maria
    Pont-Sunyer, Claustre
    Santos, Meritxell
    Casellas, Aina
    Valldeoriola, Francesc
    Compta, Yaroslau
    Marti, Maria Jose
    Mullol, Joaquim
    JOURNAL OF PARKINSONS DISEASE, 2020, 10 (03) : 951 - 958
  • [10] Roco Proteins and the Parkinson's Disease-Associated LRRK2
    Liao, Jingling
    Hoang, Quyen Q.
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2018, 19 (12)
12345